| 000 | 01519 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250517065535.0 | ||
| 264 | 0 | _c20161005 | |
| 008 | 201610s 0 0 eng d | ||
| 022 | _a2157-1422 | ||
| 024 | 7 |
_a10.1101/cshperspect.a026260 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAblain, Julien | |
| 245 | 0 | 0 |
_ap53 as an Effector or Inhibitor of Therapy Response. _h[electronic resource] |
| 260 |
_bCold Spring Harbor perspectives in medicine _cDec 2015 |
||
| 300 |
_aa026260 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aArsenic Trioxide |
| 650 | 0 | 4 |
_aArsenicals _xadministration & dosage |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Promyelocytic, Acute _xdrug therapy |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aOncogene Proteins, Fusion _xgenetics |
| 650 | 0 | 4 |
_aOxides _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTretinoin _xadministration & dosage |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xmetabolism |
| 700 | 1 | _aPoirot, Brigitte | |
| 700 | 1 | _aEsnault, Cécile | |
| 700 | 1 | _aLehmann-Che, Jacqueline | |
| 700 | 1 | _ade Thé, Hugues | |
| 773 | 0 |
_tCold Spring Harbor perspectives in medicine _gvol. 6 _gno. 1 _gp. a026260 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1101/cshperspect.a026260 _zAvailable from publisher's website |
| 999 |
_c25514678 _d25514678 |
||